Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Bryce

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
Science Translational Medicine|January 11, 2023
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancerKaran K Budhraja, Bradon R McDonald, Michelle D Stephens, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023Edward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in OncologyEdward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
Cancer Cell|November 18, 2022
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Minetta C Liu, Eric A Klein, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
Science Translational Medicine|January 11, 2023
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancerKaran K Budhraja, Bradon R McDonald, Michelle D Stephens, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023Edward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in OncologyEdward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
Cancer Cell|November 18, 2022
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Minetta C Liu, Eric A Klein, et al.
Pageof 3